Non-small Cell Lung Cancer (NSCLC) Clinical Trial
Official title:
A Phase II Study of WX-0593 Combined With Concurrent Chemoradiotherapy in the Treatment of Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutation of ALK or ROS1
The aim of this trial is to evaluate the safety of WX-0593 combined with concurrent chemoradiotherapy in unresectable, locally advanced non-small cell lung cancer (NSCLC) with activating mutation of ALK or ROS1. This trial consists of two parts. In Part 1, approximately 8 patients will be included and receive WX-0593 maintenance until disease progression or unacceptable toxicity. In Part 2, approximately 32 patients will be included and receive WX-0593 monotherapy for 1-2 cycles and subsequently with concurrent chemoradiation, followed by WX-0593 maintenance until disease progression or unacceptable toxicity.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | May 30, 2026 |
Est. primary completion date | April 30, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Male or female aged 18 years or older; - Pathologically confirmed NSCLC who present with investigator-assessed previously untreated, unresectable, locally advanced (Stage II?III) disease (according to TMN staging of AJCC version 8); - Has active mutation of ALK or ROS1; - Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1; - Has at least one evaluable lesion (according to RECIST 1.1); - Have adequate pulmonary function test as a forced expiratory volume in 1 second (FEV1) >50% of predicted normal volume and carbon monoxide lung diffusing capacity (DLCO) >40% of predicted normal value; - Have adequate organ and marrow function; - If participant is a woman of childbearing potential (WOCBP), must agree to follow the contraceptive guidance from written informed consent until at least 180 days after the last dose of study treatment. The female participant should have negative serum pregnancy test within 7 days prior to the first dose of study drug, and not breastfeeding; - A male participant must agree to use contraception from written informed consent until at least 180 days after the last dose of study treatment. Exclusion Criteria: - Diagnosed other malignant tumor besides NSCLC within 5 years prior to study entry; - Mixed small cell and non-small cell lung cancer histology; - Has received prior therapy with any ALK TKI; - Has a history of extensive diffuse/bilateral interstitial fibrosis, or grade 3 or 4 pulmonary fibrosis or interstitial lung disease prior to the first dose of study drug. Has a known history of active tuberculosis; severe infection within 4 weeks prior to study entry; - History of primary immunodeficiency; - Active or prior documented autoimmune disease within the past 2 years. NOTE: Patients with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded. |
Country | Name | City | State |
---|---|---|---|
China | Shandong Cancer Hospital and Institute | Jinan | Shandong |
Lead Sponsor | Collaborator |
---|---|
Jinming Yu |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants Who Develop Grade 3 or Higher drug-related Pneumonitis | within 90 days after radiation therapy | ||
Secondary | Progression Free Survival (PFS) | PFS is defined as the time from the first dose of study drug to the first documented disease progression or death due to any cause, whichever occurs first | 24 months | |
Secondary | Overall Survival (OS) | OS is defined as the time from the first dose of study drug to death due to any cause. | 24 months | |
Secondary | Adverse Events (AEs) | Percentage of participants who experienced one or more AEs. | 24 months | |
Secondary | Disease control rate (DCR) | 24 months | ||
Secondary | Objective response rate (ORR) | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06040541 -
Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT03667820 -
Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC
|
Phase 2 | |
Completed |
NCT02025114 -
Selumetinib in Combination With Gefitinib in NSCLC Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT01994057 -
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
|
||
Completed |
NCT01438307 -
Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT01193959 -
Pemetrexed in Advanced Non-small Cell Lung Cancer
|
||
Recruiting |
NCT01028729 -
A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC)
|
Phase 4 | |
Completed |
NCT00770588 -
Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)
|
Phase 4 | |
Active, not recruiting |
NCT05462717 -
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
|
Phase 1 | |
Completed |
NCT01951157 -
A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
|
Phase 2 | |
Recruiting |
NCT01964157 -
An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement
|
Phase 2 | |
Active, not recruiting |
NCT04026412 -
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
|
Phase 3 | |
Recruiting |
NCT05585320 -
A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03260491 -
HER3-DXd in Metastatic or Unresectable Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT05207423 -
A Chart Review Study of Adults With Advanced NSCLC
|
||
Terminated |
NCT02608528 -
Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy
|
||
Completed |
NCT01463423 -
Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)
|
N/A | |
Recruiting |
NCT02927340 -
A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions
|
Phase 2 | |
Recruiting |
NCT02521051 -
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
|
Phase 1/Phase 2 |